Down Syndrome Differential Diagnoses
- Author: Harold Chen, MD, MS, FAAP, FACMG; Chief Editor: Bruce Buehler, MD more...
Diagnostic Considerations
The presence of 8 or more of the characteristic clinical findings (see Presentation) leads to a definite diagnosis of Down syndrome. Chromosomal analysis is recommended and of utmost importance in doubtful cases.[53, 54, 55]
In addition to the differential diagnosis, other problems to be considered include the following:
- 49,XXXXY chromosome
- Cretinism
- Chromosome 21, mosaic 21 syndrome
- Chromosome 21, translocation 21 syndrome
- Other high-order multiple X chromosomes
- Other peroxisomal disorders
- Zellweger syndrome
Differential Diagnoses
Lejeune J. Le mongolisme. Premier example d'aberration autosomique humaine. Ann Genet. 1959;1:41-9.
Jacobs PA, Baikie AG, Court Brown WM, Strong JA. The somatic chromosomes in mongolism. Lancet. Apr 4 1959;1(7075):710. [Medline].
Peterson MB, Mikkelsen M. Nondisjunction in trisomy 21: origin and mechanisms. Cytogenet Cell Genet. 2000;91:199-203.
Down JL. Observations on an ethnic classification of idiots. 1866. Ment Retard. Feb 1995;33(1):54-6. [Medline].
LEJEUNE J, GAUTIER M, TURPIN R. [Study of somatic chromosomes from 9 mongoloid children]. C R Hebd Seances Acad Sci. Mar 16 1959;248(11):1721-2. [Medline].
Levenson D. Talking about Down syndrome. Am J Med Genet A. Feb 15 2009;149A(4):vii-viii. [Medline].
[Guideline] Hartway S. A parent's guide to the genetics of Down syndrome. Adv Neonatal Care. Feb 2009;9(1):27-30. [Medline].
Ranweiler R. Assessment and care of the newborn with Down syndrome. Adv Neonatal Care. Feb 2009;9(1):17-24; Quiz 25-6. [Medline].
Reeves RH, Baxter LL, Richtsmeier JT. Too much of a good thing: mechanisms of gene action in Down syndrome. Trends Genet. Feb 2001;17(2):83-8. [Medline].
Cheon MS, Shim KS, Kim SH, Hara A, Lubec G. Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: Challenging the gene dosage effect hypothesis (Part IV). Amino Acids. Jul 2003;25(1):41-7. [Medline].
[Guideline] American College of Obstetricians and Gynecologists. Screening for fetal chromosomal abnormalities. National Guideline Clearinghouse. Jan 2007:[Full Text].
Canfield MA, Honein MA, Yuskiv N, Xing J, Mai CT, Collins JS. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Res A Clin Mol Teratol. Nov 2006;76(11):747-56. [Medline].
Coppus AM, Evenhuis HM, Verberne GJ, et al. Survival in elderly persons with Down syndrome. J Am Geriatr Soc. Dec 2008;56(12):2311-6. [Medline].
[Guideline] Cohen WI, ed. Health care guidelines for individuals with Down syndrome (Down syndrome preventative medical check list). Down Syndrome Q. 1996;1(2):1-10. [Full Text].
Nieuwenhuis-Mark RE. Diagnosing Alzheimer's dementia in Down syndrome: Problems and possible solutions. Res Dev Disabil. 2009;30(5):827-838.
Kusters MA, Verstegen RH, Gemen EF, de Vries E. Intrinsic defect of the immune system in children with Down syndrome: a review. Clin Exp Immunol. May 2009;156(2):189-93. [Medline]. [Full Text].
Vis JC, Duffels MG, Winter MM, Weijerman ME, Cobben JM, Huisman SA. Down syndrome: a cardiovascular perspective. J Intellect Disabil Res. May 2009;53(5):419-25. [Medline].
Lanfranchi S, Carretti B, Spanò G, Cornoldi C. A specific deficit in visuospatial simultaneous working memory in Down syndrome. J Intellect Disabil Res. May 2009;53(5):474-83. [Medline].
Levorato MC, Roch M, Beltrame R. Text comprehension in Down syndrome: the role of lower and higher level abilities. Clin Linguist Phon. Apr 2009;23(4):285-300. [Medline].
Salomon LJ, Bernard M, Amarsy R, Bernard JP, Ville Y. The impact of crown-rump length measurement error on combined Down syndrome screening: a simulation study. Ultrasound Obstet Gynecol. May 2009;33(5):506-11. [Medline].
Scherbenske JM, Benson PM, Rotchford JP, James WD. Cutaneous and ocular manifestations of Down syndrome. J Am Acad Dermatol. May 1990;22(5 Pt 2):933-8. [Medline].
Wilms A, Dummer R. [Elastosis perforans serpiginosa in Down syndrome]. Hautarzt. Dec 1997;48(12):923-5. [Medline].
Daneshpazhooh M, Nazemi TM, Bigdeloo L, Yoosefi M. Mucocutaneous findings in 100 children with Down syndrome. Pediatr Dermatol. May-Jun 2007;24(3):317-20. [Medline].
Masjkey D, Bhattacharya S, Dhungel S, Jha CB, Shrestha S, Ghimire SR, et al. Utility of phenotypic dermal indices in the detection of Down syndrome patients. Nepal Med Coll J. Dec 2007;9(4):217-21. [Medline].
Popova G, Paterson WF, Brown A, Donaldson MD. Hashimoto's thyroiditis in Down's syndrome: clinical presentation and evolution. Horm Res. 2008;70(5):278-84. [Medline].
Shalitin S, Phillip M. Autoimmune thyroiditis in infants with Down's syndrome. J Pediatr Endocrinol. 2002;15:649-652.
Idris I, O'Malley BP. Thyrotoxicosis in Down's and Turner's syndromes: the likelihood of Hashimoto's thyroiditis as the underlying aetiology. Int J Clin Pract. 2000;54:272-273.
Rudberg C, Johansson H, Akerstrom G, Tuvema T, Karlsson FA. Graves' disease in children and adolescents. Late results of surgical treatment. Eur J Endocrinol. 1996;134:710-7.
Zwaan MC, Reinhardt D, Hitzler J, Vyas P. Acute leukemias in childrenwith Down syndrome. Pediatr Clin N Am. 2008;55:53-70.
Lerner LH, Wiss K, Gellis S, Barnhill R. An unusual pustular eruption in an infant with Down syndrome and a congenital leukemoid reaction. J Am Acad Dermatol. Aug 1996;35(2 Pt 2):330-3. [Medline].
Krivit W, Good RA. The simultaneous occurrence of leukemia and mongolism; report offour cases. AMA J Dis Child. 1956;91:218-222.
Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. Jan 15 2000;355(9199):165-9. [Medline].
Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer. Jan 2005;5(1):11-20. [Medline].
Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. Jun 2005;37(6):613-9. [Medline].
Bhatt S, Schreck R, Graham JM, Korenberg JR, Hurvitz CG, Fischel-Ghodsian N. Transient leukemia with trisomy 21: description of a case and review of the literature. Am J Med Genet. Sep 25 1995;58(4):310-4. [Medline].
Roderick JA, Bradshaw WT. Transient myeloproliferative disorder in a newborn with Down syndrome. Adv neonat Care. 2008;8:208-218.
Gamis A, Hilden J. Transient myleoproliferative disorder with too few data and many unanswered questions: does it contain an important piece of the puzzle to understanding hemataopoiesis and acute myelogenous leukemia?. J Pediatr Hematol Oncol. 2002;24:2-5.
Ma SK, Wan TS, Chan GC, Ha SY, Fung LF, Chan LC. Relationship between transient abnormal myelopoiesis and acute megakaryoblastic leukaemia in Down's syndrome. Br J Haematol. Mar 2001;112(3):824-5. [Medline].
Magalhaes IQ, Splendore A, Emerenciano M, et al. Transient neonatal myeloproliferative disorder without Down syndrome and detection of GATA1 mutation. J Pediatr Hematol Oncol. Jan 2005;27(1):50-2. [Medline].
Ahmed M, Sternberg A, Hall G, et al. Natural history of GATA-1 mutations in Down syndrome. Blood. 2004;103:2480-2489.
Taub J. Down syndrome and megakaryocytic leukemia/transient myeloproliferative disorder: when does it begin?. Blood. 2003;101:4228-4300.
Al Kasim F, Doyle JJ, Massey GV, et al. Incidence and treatment of potentially lethal diseasesin transient leukemia of Down syndrome: Pediatric Oncology Group Study. J Pediatr Hematol Oncol. 2002;24:9-13.
Massey GV, Zipursky A, Chang MN, Doyle JJ, Nasim S, Taub JW. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood. Jun 15 2006;107(12):4606-13. [Medline].
Ringman JM, Rao N, Lu PH, Cederbaum S. Mosaicism for trisomy 21 in a patient with young-onset dementia. A case report and brief literature review. Arch Neurol. 2008;65:412-415.
Papavassiliou P, York TP, Gursoy N, Hill G, Nicely LV, Sundaram U. The phenotype of persons having mosaicism for trisomy 21/Down syndrome reflects the percentage of trisomic cells present in different tissues. Am J Med Genet A. Feb 15 2009;149A(4):573-83. [Medline].
Baum RA, Nash PL, Foster JE, Spader M, Ratliff-Schaub K, Coury DL. Primary care of children and adolescents with down syndrome: an update. Curr Probl Pediatr Adolesc Health Care. Sep 2008;38(8):241-61. [Medline].
Rabin KR, Whitlock JA. Malignancy in children with trisomy 21. Oncologist. Feb 2009;14(2):164-73. [Medline].
Mik G, Gholve PA, Scher DM, Widmann RF, Green DW. Down syndrome: orthopedic issues. Curr Opin Pediatr. Feb 2008;20(1):30-6. [Medline].
Rogers PT, Roizen NJ, Capone GT. Down syndrome. In: Capute AJ, Accardo PJ. Developmental disabilities in infancy and childhood. 2nd. 1996:221-224.
Pueschel SM, Scola FH. Atlantoaxial instability in individuals with Down Syndrome: epidemiologic, radiographic, and clinical studies. Pediatrics. 1987;80:555-560.
Myers BA, Pueschel SM. Psychiatric disorders in persons with Down syndrome. J Nerv Ment Dis. Oct 1991;179(10):609-13. [Medline].
Rice C. Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders—autism and developmental disabilities monitoring network, 14 sites, United States,2002. MMWR CDC Surveill Summ. 2007;56:12-28.
Driscoll DA, Morgan MA, Schulkin J. Screening for Down syndrome: changing practice of obstetricians. Am J Obstet Gynecol. Apr 2009;200(4):459.e1-9. [Medline].
Summerfield P. Prenatal screening for Down's syndrome: balanced debate needed. Lancet. Feb 28 2009;373(9665):722. [Medline].
Fransen MP, Hajo Wildschut, Vogel I, Mackenbach J, Steegers E, Essink-Bot ML. Information about prenatal screening for Down syndrome: ethnic differences in knowledge. Patient Educ Couns. Nov 2009;77(2):279-88. [Medline].
Dreux S, Olivier C, Dupont JM, Leporrier N, Oury JF. Maternal serum screening in cases of mosaic and translocation Down syndrome. Prenat Diagn. Aug 2008;28(8):699-703. [Medline].
Cuckle H. Biochemical screening for Down syndrome. Eur J Obstet Gynecol Reprod Biol. Sep 2000;92(1):97-101. [Medline].
Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet. Aug 1 1998;352(9125):343-6. [Medline].
Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol. Mar 2005;25(3):221-6. [Medline].
Chiu RW, Akolekar R, Zheng YW, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ. Jan 11 2011;342:c7401. [Medline]. [Full Text].
Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study. Genet Med. Nov 2011;13(11):913-920. [Medline].
Warburton D, Dallaire L, Thangavelu M, Ross L, Levin B, Kline J. Trisomy recurrence: a reconsideration based on North American data. Am J Hum Genet. Sep 2004;75(3):376-85. [Medline].
Nussbaum RL, McInnes RR, Willard HF. Thompson and Thompson genetics in medicine. 6th Revised Reprint Edition. Philadelphia: W.B. Saunders; 2004.
Tolmie J. Down syndrome and other autosomal trisomies. In: Rimoin DL, Connor JM, Pyeritz RE, Korf BR. Emery and Rimoin's Principles and Practice of Medical Genetics. 4th edition. 2002:1129-1183.
Liyanage S, Barnes J. The eye and Down's syndrome. Br J Hosp Med (Lond). Nov 2008;69(11):632-4. [Medline].
Chen H, Woolley PV Jr. A developmental assessment chart for non-institutionalized Down syndrome children. Growth. Jun 1978;42(2):157-65. [Medline].
Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. Jun 2008;31(6):618-24. [Medline].
Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol. Jul 2004;191(1):45-67. [Medline].
Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. Apr 1999;13(4):231-7. [Medline].

